Cited by 284Neurofibromatosis and Schwannoma CasesProtein Tyrosine PhosphatasesAcute Myeloid Leukemia Research

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Nf1 deficiency causes Ras-Dediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia

Largaespada, David A., Brannan, Camilynn I., Jenkins, Nancy A., Copeland, Neal G.·1996·Nature Genetics

Open this paper in CoChat — free account

Abstract

The Ras signal transduction pathway is often deregulated in human myeloid leukaemia. For example, activating point mutations in RAS genes are found in some patients with juvenile chronic myelogenous leukaemia (JCML), while other patients with JCML show loss of the neurofibromatosis type 1 (NF1) gene, a Ras GTPase activating protein. By generating mice whose haematopoietic system is reconsituted with Nf1 deficient haematopoietic stem cells we show that Nf1 gene loss, by itself, is sufficient to produce the myeloproliferative symptoms associated with human JCML. We also provide evidence to indicate that Nf1 gene loss induces myeloproliferative disease through a Ras-mediated hypersensitivity to granulocyte/macrophage-colony stimulating factor (GM-CSF). Finally, we describe a genetic screen for identifying genes that cooperate with Nf1 gene loss during progression to acute myeloid leukaemia.

Integrity signals

Registry

Crossref · 10.1038/ng0296-137

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Neurofibromatosis, Phenotype, Natural History, and Pathogenesis
Riccardi, V. M., & Smirniotopoulos, J. G. (1992) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199211000-00009 · Cited by 897
Tumour predisposition in mice heterozygous for a targeted mutation in Nf1
Jacks, T., Shih, T. S., Schmitt, E. M., Bronson, R. T., Bernards, A., & Weinberg, R. A. (1994) · Nature Genetics · doi:10.1038/ng0794-353 · Cited by 780
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients
Basu, T. N., Gutmann, D. H., Fletcher, J. A., Glover, T. W., Collins, F. S., & Downward, J. (1992) · Nature · doi:10.1038/356713a0 · Cited by 669
BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein
Pendergast, A. M., Quilliam, L. A., Cripe, L. D., Bassing, C. H., Dai, Z., Li, N., Batzer, A., Rabun, K. M., Der, C. J., Schlessinger, J., et al. (1993) · Cell · doi:10.1016/s0092-8674(05)80094-7 · Cited by 657
Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues.
Brannan, C. I., Perkins, A. S., Vogel, K. S., Ratner, N., Nordlund, M. L., Reid, S. W., Buchberg, A. M., Jenkins, N. A., Parada, L. F., & Copeland, N. G. (1994) · Genes & Development · doi:10.1101/gad.8.9.1019 · Cited by 641
Self-citation
Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis
DeClue, J. E., Papageorge, A. G., Fletcher, J. A., Diehl, S. R., Ratner, N., Vass, W. C., & Lowy, D. R. (1992) · Cell · doi:10.1016/0092-8674(92)90407-4 · Cited by 580
Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells
Hestdal, K., Ruscetti, F. W., Ihle, J. N., Jacobsen, S. E. W., Dubois, C. M., Kopp, W. C., Longo, D., & Keller, J. R. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.1.22 · Cited by 464
Loss of The Normal NF1 Allele from the Bone Marrow of Children with Type 1 Neurofibromatosis and Malignant Myeloid Disorders
Shannon, K., O'Connell, P., Martin, G. A., Paderanga, D., Olson, K., Dinndorf, P. A., & McCormick, F. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300903 · Cited by 440
Bcr‐Abl oncoproteins bind directly to activators of the Ras signalling pathway.
Puil, L. J., Liu, J., Gish, G., Mbamalu, G., Bowtell, D. D. L., Pelicci, P. G., Arlinghaus, R. B., & Pawson, T. J. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06319.x · Cited by 438
Receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3, and interleukin-5
Miyajima, A., Mui, A. L.-F., Ogorochi, T., & Sakamaki, K. (1993) · Blood · doi:10.1182/blood.v82.7.1960.bloodjournal8271960 · Cited by 414

Show all 33 references

Research works printed but not linked: 2

Hope, D.G. & Mulvihill, J.J. Malignancy in neunofibromatosis. Adv. Neurol. 29, 33–56 (1981).
Gonda, T.J. Molecular and cellular activities of Myb: regulation in normal hemopoiesis and transformation. Seminars in virology 2, 351–361 (1991).

Sorted by citations

Items 101–200 of 284

Testing of new agents in childhood cancer preclinical models: meeting summary.
Houghton, P. J., Adamson, P. C., Blaney, S. M., Fine, H. A., Gorlick, R. G., Haber, M., Helman, L. J., Hirschfeld, S., Hollingshead, M. G., Israel, M. A., et al. (2002) · PubMed · Cited by 63
RAS, FLT3, and TP53 mutations in therapy‐related myeloid malignancies with abnormalities of chromosomes 5 and 7
Side, L. E., Curtiss, N. P., Teel, K., Kratz, C. P., Wang, P. W., Larson, R. A., Beau, M. M. L., & Shannon, K. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10320 · Cited by 62
Germline Mutations in Components of the Ras Signaling Pathway in Noonan Syndrome and Related Disorders
Kratz, C. P., Schubbert, S., Bollag, G. E., Niemeyer, C. M., Shannon, K., & Zenker, M. (2006) · Cell Cycle · doi:10.4161/cc.5.15.3128 · Cited by 59
Advances in the Genetics of High-Risk Childhood B-Progenitor Acute Lymphoblastic Leukemia and Juvenile Myelomonocytic Leukemia: Implications for Therapy
Loh, M. L., & Mullighan, C. G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1936 · Cited by 59
PU.1, Interferon Regulatory Factor (IRF) 2, and the Interferon Consensus Sequence-binding Protein (ICSBP/IRF8) Cooperate to Activate NF1 Transcription in Differentiating Myeloid Cells
Huang, W., Horvath, E., & Eklund, E. A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607760200 · Cited by 58
Oncogenic interaction between BCR-ABL andNUP98-HOXA9 demonstrated by the use of an in vitro purging culture system
Mayotte, N., Roy, D., Yao, J., KROON, E. J., & Sauvageau, G. (2002) · Blood · doi:10.1182/blood-2002-04-1244 · Cited by 58
Brain tumors in neurofibromatosis type 1
Costa, A. D. A., & Gutmann, D. H. (2019) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz040 · Cited by 57
An unexpected new role of mutant Ras: perturbation of human embryonic development
Kratz, C. P., Niemeyer, C. M., & Zenker, M. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0135-4 · Cited by 57
Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice
Mahgoub, N., Taylor, B. R., Beau, M. M. L., Gratiot, M., Carlson, K. M., Atwater, S. K., Jacks, T., & Shannon, K. (1999) · Blood · doi:10.1182/blood.v93.11.3617 · Cited by 56
Juvenile Myelomonocytic Leukemia: Molecular Pathogenesis Informs Current Approaches to Therapy and Hematopoietic Cell Transplantation
Dvorak, C. C., & Loh, M. L. (2014) · Frontiers in Pediatrics · doi:10.3389/fped.2014.00025 · Cited by 55
NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome
Eisfeld, A., Kohlschmidt, J., Mrózek, K., Mims, A. S., Walker, C. J., Blachly, J. S., Nicolet, D., Orwick, S. J., Maharry, S. E., Carroll, A. J., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0147-4 · Cited by 54
Quantitative effects of Nf1 inactivation on in vivo hematopoiesis
Zhang, Y., Taylor, B. R., Shannon, K., & Clapp, D. W. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12758 · Cited by 54
Neurofibromatosis type 1-related gastrointestinal stromal tumors: a special reference to loss of heterozygosity at 14q and 22q
Yamamoto, H., Tobo, T., Nakamori, M., Imamura, M., Kojima, A., Oda, Y., Nakamura, N., Takahira, T., Yao, T., & Tsuneyoshi, M. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0514-z · Cited by 54
Inhibition of Granulocyte-Macrophage Colony-Stimulating Factor Prevents Dissemination and Induces Remission of Juvenile Myelomonocytic Leukemia in Engrafted Immunodeficient Mice
Iversen, P. O., Lewis, I. D., Turczynowicz, S., Hasle, H., Niemeyer, C. M., Schmiegelow, K., Bastiras, S., Biondi, A., Hughes, T. P., & Lopez, A. F. (1997) · Blood · doi:10.1182/blood.v90.12.4910 · Cited by 54
A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast-like cells
El‐Hoss, J., Sullivan, K., Cheng, T. L., Yu, N. Y. C., Bobyn, J. D., Peacock, L., Mikulec, K., Baldock, P. A. J., Alexander, I. E., Schindeler, A., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.528 · Cited by 53
A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene
Yin, B., Delwel, R., Valk, P. J. M., Wallace, M. R., Loh, M. L., Shannon, K., & Largaespada, D. A. (2008) · Blood · doi:10.1182/blood-2008-03-144436 · Cited by 53
Self-citation
Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment
Bellampalli, S. S., & Khanna, R. (2019) · Pain · doi:10.1097/j.pain.0000000000001486 · Cited by 52
Lymphoproliferative defects in mice lacking the expression of neurofibromin: functional and biochemical consequences ofNf1 deficiency in T-cell development and function
Ingram, D. A., Zhang, L., McCarthy, J., Wenning, M. J., Fisher, L., Yang, F., Clapp, D. W., & Kapur, R. (2002) · Blood · doi:10.1182/blood-2002-03-0734 · Cited by 52
Myelodysplastic syndrome: review of the cytogenetic and molecular data
Mhawech, P., & Saleem, A. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00101-9 · Cited by 51
Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell
Cooper, L. J. N., Shannon, K., Loken, M. R., Weaver, M., Stephens, K. G., & Sievers, E. L. (2000) · Blood · doi:10.1182/blood.v96.6.2310 · Cited by 50
Current Treatment of Juvenile Myelomonocytic Leukemia
Mayerhofer, C., Niemeyer, C. M., & Flotho, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143084 · Cited by 49
Ras-induced cellular events
Rebollo, A. (2000) · Molecular Membrane Biology · doi:10.1080/09687680050117093 · Cited by 50
Regulation of Immune Responses and Hematopoiesis by the Rap1 Signal
Minato, N., Kometani, K., & Hattori, M. (2007) · Advances in immunology · doi:10.1016/s0065-2776(06)93006-5 · Cited by 49
Classification of chronic myeloid disorders: From Dameshek towards a semi-molecular system
Tefferi, A., & Gilliland, G. D. (2006) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.07.001 · Cited by 47
Rap1 and SPA-1 in hematologic malignancy
Kometani, K., Ishida, D., Hattori, M., & Minato, N. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.06.004 · Cited by 45
The role of the immune system in neurofibromatosis type 1-associated nervous system tumors
Karmakar, S., & Reilly, K. M. (2016) · CNS Oncology · doi:10.2217/cns-2016-0024 · Cited by 44
THE MOLECULAR PATHOPHYSIOLOGY OF MYELOID LEUKAEMIAS: Ras REVISITED
Byrne, J., & Marshall (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00554.x · Cited by 43
Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic leukemic cells by the granulocyte-macrophage colony- stimulating factor analogue E21R
Iversen, P., Rodwell, R., Pitcher, L. A., Taylor, K., & Lopez, A. F. (1996) · Blood · doi:10.1182/blood.v88.7.2634.bloodjournal8872634 · Cited by 43
Tie2-Cre–Induced Inactivation of a Conditional Mutant Nf1 Allele in Mouse Results in a Myeloproliferative Disorder that Models Juvenile Myelomonocytic Leukemia
Gitler, A. D., Kong, Y., Choi, J. K., Zhu, Y., Pear, W. S., & Epstein, J. A. (2004) · Pediatric Research · doi:10.1203/01.pdr.0000113462.98851.2e · Cited by 42
Sensory Neurons From Nf1 Haploinsufficient Mice Exhibit Increased Excitability
Wang, Y., Nicol, G. D., Clapp, D. W., & Hingtgen, C. M. (2005) · Journal of Neurophysiology · doi:10.1152/jn.00489.2005 · Cited by 42
Leukemia-Associated, Constitutively Active Mutants of SHP2 Protein Tyrosine Phosphatase Inhibit NF1 Transcriptional Activation by the Interferon Consensus Sequence Binding Protein
Huang, W., Saberwal, G., Horvath, E., Zhu, C., Lindsey, S., & Eklund, E. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00036-06 · Cited by 41
Transcriptional Repression of the Neurofibromatosis-1 Tumor Suppressor by the t(8;21) Fusion Protein
Yang, G., Khalaf, W. F., van de Locht, L. T., Jansen, J. H., Gao, M., Thompson, M. A., van der Reijden, B. A., Gutmann, D. H., Delwel, R., Clapp, D. W., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.14.5869-5879.2005 · Cited by 40
Integration of SNP and mRNA Arrays with MicroRNA Profiling Reveals That MiR-370 Is Upregulated and Targets NF1 in Acute Myeloid Leukemia
García-Ortí, L., Cristóbal, I., Cirauqui, C., Guruceaga, E., Marcotegui, N., Calasanz, M. J., Castelló-Cros, R., & Odero, M. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047717 · Cited by 40
Atypical Cellular Disorders
Arceci, R. J., Longley, B. J., & Emanuel, P. D. (2002) · Hematology · doi:10.1182/asheducation-2002.1.297 · Cited by 38
Childhood Myelodysplastic Syndrome: Focus on the Approach to Diagnosis and Treatment of Juvenile Myelomonocytic Leukemia
Loh, M. L. (2010) · Hematology · doi:10.1182/asheducation-2010.1.357 · Cited by 37
Juvenile myelomonocytic leukemia
Niemeyer, C. M., & Kratz, C. P. (2003) · Current Oncology Reports · doi:10.1007/s11912-003-0013-y · Cited by 37
Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia
Morgan, M. A., Ganser, A., & Reuter, C. W. (2003) · Leukemia · doi:10.1038/sj.leu.2403024 · Cited by 35
Scientific and clinical opportunities for modeling blood disorders with embryonic stem cells
Lensch, M. W., & Daley, G. Q. (2005) · Blood · doi:10.1182/blood-2005-07-2991 · Cited by 35
Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells
Staser, K. W., Yang, F., & Clapp, D. W. (2010) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328339511b · Cited by 35
Genetic heterogeneity in acute myeloid leukemia: maximizing information flow from MuLV mutagenesis studies
Largaespada, D. A. (2000) · Leukemia · doi:10.1038/sj.leu.2401852 · Cited by 34
Self-citation
Ras Dependent Paracrine Secretion of Osteopontin by Nf1+/− Osteoblasts Promote Osteoclast Activation in a Neurofibromatosis Type I Murine Model
Li, H., Liu, Y., Zhang, Q., Jing, Y., Shi, C., Song, Z.-H., Yan, J., Li, Y., Wu, X., Zhang, X., et al. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e3181a1c607 · Cited by 33
Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia
Archambeault, S., Flores, N. J., Yoshimi, A., Kratz, C. P., Reising, M., Fischer, A., Noellke, P., Locatelli, F., Sedláček, P., Flotho, C., et al. (2007) · Blood · doi:10.1182/blood-2007-06-093302 · Cited by 33
Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth
Iversen, P. O., Emanuel, P. D., & Sioud, M. (2002) · Blood · doi:10.1182/blood.v99.11.4147 · Cited by 33
Tumor Suppressor Genes and Human Cancer
Brown, M. A. (1997) · Advances in genetics · doi:10.1016/s0065-2660(08)60307-7 · Cited by 32
Stimulus-evoked release of neuropeptides is enhanced in sensory neurons from mice with a heterozygous mutation of the Nf1 gene
Hingtgen, C. M., Roy, S., & Clapp, D. W. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.09.030 · Cited by 31
Deletion ofNf1in Neurons Induces Increased Axon Collateral Branching after Dorsal Root Injury
Romero‐Ortega, M. I., Lin, L., Lush, M. E., Lei, L., Parada, L. F., & Zhu, Y. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4363-06.2007 · Cited by 31
The role of Ras and other low molecular weight guanine nucleotide (GTP)-binding proteins during hematopoietic cell differentiation
Scheele, J. S., Räpple, D., & Lübbert, M. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000675 · Cited by 31
A Critical Review of Animal Models Used in Acute Myeloid Leukemia Pathophysiology
Skayneh, H., Jishi, B., Hleihel, R., Hamieh, M., Darwiche, N., Bazarbachi, A. A., El-Sabban, M. E., & Hajj, H. E. (2019) · Genes · doi:10.3390/genes10080614 · Cited by 32
Regulation of Ras signal transduction during T cell development and activation.
Lapinski, P. E., & King, P. D. (2012) · PubMed Central · Cited by 30
Repressible transgenic model of NRAS oncogene–driven mast cell disease in the mouse
Wiesner, S. M., Jones, J. M., Hasz, D. E., & Largaespada, D. A. (2005) · Blood · doi:10.1182/blood-2004-08-3306 · Cited by 29
Self-citation
Nf1 gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways
Yin, B., Morgan, K. J., Hasz, D. E., Mao, Z., & Largaespada, D. A. (2005) · Leukemia · doi:10.1038/sj.leu.2404033 · Cited by 28
Self-citation
Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia
Locatelli, F., Algeri, M., Merli, P., & Strocchio, L. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2018.1421937 · Cited by 27
Chronic myeloproliferative disorders
Niemeyer, C. M., & Locatelli, F. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511471001.023 · Cited by 27
Loss of the Nf1 Tumor Suppressor Gene Decreases Fas Antigen Expression in Myeloid Cells
Hiatt, K. K., Ingram, D. A., Huddleston, H. M., Spandau, D. F., Kapur, R., & Clapp, D. W. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63233-6 · Cited by 26
Reconstitution of the NF1 GAP-related domain in NF1-deficient human Schwann cells
Thomas, S. L., Deadwyler, G., Tang, J. M., Stubbs, E. B., Muir, D., Hiatt, K. K., Clapp, D. W., & Vries, G. H. D. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.07.159 · Cited by 29
Juvenile Myelomonocytic Leukemia
Yoshimi, A., Kojima, S., & Hirano, N. (2009) · Pediatric Drugs · doi:10.2165/11316200-000000000-00000 · Cited by 26
Juvenile myelomonocytic leukemia
Kratz, C. P., & Niemeyer, C. M. (2005) · Hematology · doi:10.1080/10245330512331390078 · Cited by 25
β common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice
Kim, A., Morgan, K. J., Hasz, D. E., Wiesner, S. M., Lauchle, J., Geurts, J. L., Diers, M. D., Le, D., Kogan, S. C., Parada, L. F., et al. (2006) · Blood · doi:10.1182/blood-2006-05-025395 · Cited by 25
Self-citation
Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice
Caudell, D. L., Harper, D. P., Novak, R. L., Pierce, R. M., Slape, C. I., Wolff, L., & Aplan, P. D. (2009) · Blood · doi:10.1182/blood-2009-04-216184 · Cited by 24
Contribution of oncogenes and tumor suppressor genes to myeloid leukemia
Wolff, L. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00006-1 · Cited by 24
The prognostic significance of bone marrow levels of neurofibromatosis‐1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome
Lu, D., Nounou, R., Beran, M., Estey, E., Manshouri, T., Kantarjian, H., Keating, M. J., & Albitar, M. (2003) · Cancer · doi:10.1002/cncr.11037 · Cited by 23
Mouse models of neurofibromatosis
McClatchey, A. I., & Cichowski, K. M. (2001) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(00)00026-3 · Cited by 23
Loss of neurofibromatosis-1 and p19ARF cooperate to induce a multiple tumor phenotype
King, D., Yang, G., Thompson, M. A., & Hiebert, S. W. (2002) · Oncogene · doi:10.1038/sj.onc.1205632 · Cited by 23
Tissue-specific differences in the proportion of mosaic large NF1 deletions are suggestive of a selective growth advantage of hematopoietic del(+/−) stem cells
Roehl, A. C., Mußotter, T., Cooper, D. N., Kluwe, L., Wimmer, K., Högel, J., Zetzmann, M., Vogt, J., Mautner, V., & Kehrer‐Sawatzki, H. (2011) · Human Mutation · doi:10.1002/humu.22013 · Cited by 22
The Neurofibromatosis Type 1 (Nf1) Tumor Suppressor is a Modifier of Carcinogen-Induced Pigmentation and Papilloma Formation in C57BL/6 Mice
Atit, R. P., Mitchell, K. R., Nguyen, L., Warshawsky, D., & Ratner, N. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00994.x · Cited by 22
Retroviral Integration at the Epi1 Locus Cooperates with Nf1 Gene Loss in the Progression to Acute Myeloid Leukemia
Blaydes, S. M., Kogan, S. C., Truong, B.-T., Gilbert, D. J., Jenkins, N. A., Copeland, N. G., Largaespada, D. A., & Brannan, C. I. (2001) · Journal of Virology · doi:10.1128/jvi.75.19.9427-9434.2001 · Cited by 22
Self-citation
Neurofibromatosis Type 1: Genetic and Cellular Mechanisms of Peripheral Nerve Tumor Formation
Rosenbaum, T., Patrie, K. M., & Ratner, N. (1997) · The Neuroscientist · doi:10.1177/107385849700300614 · Cited by 21
JNK inhibitors increase osteogenesis in Nf1-deficient cells
Sullivan, K., El‐Hoss, J., Little, D. G., & Schindeler, A. (2011) · Bone · doi:10.1016/j.bone.2011.09.043 · Cited by 20
Cutting Edge: Codeletion of the Ras GTPase-Activating Proteins (RasGAPs) Neurofibromin 1 and p120 RasGAP in T Cells Results in the Development of T Cell Acute Lymphoblastic Leukemia
Lubeck, B. A., Lapinski, P. E., Oliver, J. A., Ksionda, O., Parada, L. F., Zhu, Y., Maillard, I. P., Chiang, M. Y., Roose, J. P., & King, P. D. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402639 · Cited by 19
Dorsal root ganglia isolated from Nf1+/− mice exhibit increased levels of mRNA expression of voltage-dependent sodium channels
Hodgdon, K. E., Hingtgen, C. M., & Nicol, G. D. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.12.045 · Cited by 19
Oncogenic Kras Expression in Postmitotic Neurons Leads to S100A8-S100A9 Protein Overexpression and Gliosis
Ryu, M., Liu, Y., Zhong, X., Du, J., Peterson, N., Kong, G., Li, H., Wang, J., Salamat, S. M., Chang, Q., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.357772 · Cited by 22
Loss of neurofibromin Ras-GAP activity enhances the formation of cardiac blood islands in murine embryos
Yzaguirre, A. D., Padmanabhan, A., de Groh, E. D., Engleka, K. A., Li, J., Speck, N. A., & Epstein, J. A. (2015) · eLife · doi:10.7554/elife.07780 · Cited by 19
Neurofibromin Negatively Regulates Neurotrophin Signaling through p21ras in Embryonic Sensory Neurons
Vogel, K. S., El-Afandi, M. C. T., & Parada, L. F. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0836 · Cited by 19
Ral Is both Necessary and Sufficient for the Inhibition of Myeloid Differentiation Mediated by Ras
Omidvar, N., Pearn, L., Burnett, A. K., & Darley, R. L. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.10.3966-3975.2006 · Cited by 19
Mouse Models of Human Familial Cancer Syndromes
Ward, J. M., & Devor-Henneman, D. E. (2004) · Toxicologic Pathology · doi:10.1080/01926230490424680 · Cited by 19
The Ras GTPase-activating protein neurofibromin 1 promotes the positive selection of thymocytes
Oliver, J. A., Lapinski, P. E., Lubeck, B. A., Turner, J. S., Parada, L. F., Zhu, Y., & King, P. D. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.03.005 · Cited by 18
Acute myeloid leukaemia in children
Langmuir, P. B., Aplenc, R., & Lange, B. J. (2001) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.2000.0117 · Cited by 18
Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke
North, M. R., Shuga, J., Fromowitz, M., Loguinov, A. V., Shannon, K., Zhang, L., Smith, M. T., & Vulpe, C. D. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-6 · Cited by 17
Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy
Liu, Y. L., Yan, Y., Webster, C., Shao, L., Lensing, S., Ni, H., Feng, W., Colorado, N. C., Pathak, R., Xiang, Z., et al. (2016) · Blood · doi:10.1182/blood-2015-05-646216 · Cited by 17
Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency
Sachs, Z., Been, R. A., DeCoursin, K. J., Nguyen, H. T., Hassan, N. A. M., Noble-Orcutt, K. E., Eckfeldt, C. E., Pomeroy, E. J., Díaz-Flores, E., Geurts, J. L., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136002 · Cited by 17
Self-citation
Nf1 haploinsufficiency and Icsbp deficiency synergize in the development of leukemias
Koenigsmann, J., Rudolph, C., Sander, S., Kershaw, O., Gruber, A. D., Bullinger, L., Schlegelberger, B., & Carstanjen, D. (2009) · Blood · doi:10.1182/blood-2008-05-158485 · Cited by 17
Defective proliferative responses in B lymphocytes and thymocytes that lack neurofibromin
Kim, T. J., Cariappa, A., Iacomini, J., Tang, M., Shih, S., Bernards, A., Jacks, T., & Pillai, S. S. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(01)00101-8 · Cited by 17
Heterozygous inactivation of the Nf1 gene in myeloid cells enhances neointima formation via a rosuvastatin-sensitive cellular pathway
Stansfield, B. K., Bessler, W., Mali, R. S., Mund, J. A., Downing, B., Li, F., Sarchet, K. N., Distasi, M. R., Conway, S. J., Kapur, R., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds502 · Cited by 16
Pathology of the myeloproliferative diseases
George, T. I., & Arber, D. A. (2003) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(03)00093-5 · Cited by 16
Myelodysplastic Syndromes: Contemporary Biologic Concepts and Emerging Diagnostic Approaches
Vergilio, J., & Bagg, A. (2003) · Pathology Patterns Reviews · doi:10.1309/t8df-xexm-ylhw-51dg · Cited by 16
Modulation of Granulocyte-Macrophage Colony-Stimulating Factor Gene Expression by a Tumor Necrosis Factor Specific Ribozyme in Juvenile Myelomonocytic Leukemic Cells
Iversen, P. O., & Sioud, M. (1998) · Blood · doi:10.1182/blood.v92.11.4263 · Cited by 16
Systematic literature review on Parkinson's disease and Childhood Leukaemia and mode of actions for pesticides
Choi, J., Polcher, A. A., & Joas, A. (2016) · EFSA Supporting Publications · doi:10.2903/sp.efsa.2016.en-955 · Cited by 18
RAS Pathway Mutations in Juvenile Myelomonocytic Leukemia
Emanuel, P. D. (2008) · Acta Haematologica · doi:10.1159/000140632 · Cited by 15
Neurofibromatosis type 1 & Related Disorders
Ruggieri, M., Upadhyaya, M., Rocco, C. D., Gabriele, A. T., & Pascual-Castroviejo, I. (2008) · Springer eBooks · doi:10.1007/978-3-211-69500-5_3 · Cited by 15
Leukemic potential of doubly mutant Nf1 andWv hematopoietic cells
Ingram, D. A., Wenning, M. J., Shannon, K., & Clapp, D. W. (2003) · Blood · doi:10.1182/blood-2002-08-2635 · Cited by 15
Parallels between tuberous sclerosis complex and neurofibromatosis 1: Common threads in the same tapestry
Gutmann, D. H. (1998) · Seminars in Pediatric Neurology · doi:10.1016/s1071-9091(98)80006-5 · Cited by 15
Modeling myeloid leukemia tumor suppressor gene inactivation in the mouse
Shannon, K., Beau, M. M. L., Largaespada, D. A., & Killeen, N. P. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0372 · Cited by 15
Self-citation
Role of PTPN11 (SHP2) in Cancer
Chan, G., & Neel, B. G. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3649-6_4 · Cited by 13
Vav promoter-tTA conditional transgene expression system for hematopoietic cells drives high level expression in developing B and T cells
Kim, W.-I., Wiesner, S. M., & Largaespada, D. A. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.04.012 · Cited by 15
Self-citation
HOMOZYGOUS INACTIVATION OF THE NF1 GENE IN BONE MARROW CELLS FROM CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 AND MALIGNANT MYELOID DISORDERS
Ide, L. U. S., Aylor, R. T., Uce, M. I. L., & Hannon, K. E. S. (1997) · Cited by 14
IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease
Wong, S., McLaughlin, J., Cheng, D., Shannon, K., Robb, L. G., & Witte, O. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2035020100 · Cited by 14
Myeloid Leukemia: Disease Genes and Mouse Models
Copeland, N. G., & Jenkins, N. A. (1999) · KARGER eBooks · doi:10.1159/000062003 · Cited by 14
Self-citation
The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-Ras activation in Nf1-negative AML cells
Morgan, K. J., Rowley, M., Wiesner, S. M., Hasz, D. E., Ness, B. V., & Largaespada, D. A. (2007) · Leukemia Research · doi:10.1016/j.leukres.2006.11.022 · Cited by 13
Self-citation
VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease
An, W., Mohapatra, B. C., Zutshi, N., Bielecki, T. A., Goez, B. T., Luan, H., Iseka, F., Mushtaq, I., Storck, M. D., Band, V., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10638 · Cited by 12
The impact of host immune cells on the development of neurofibromatosis type 1: The abnormal immune system provides an immune microenvironment for tumorigenesis
Wei, C., Gu, S., Ren, J.-Y., Gu, Y., Xu, X., Chou, X., Lian, X., Huang, X., Li, H., Gao, Y., et al. (2019) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz037 · Cited by 12

Authors: Largaespada, D. A., Brannan, C. I., Jenkins, N. A., & Copeland, N. G.
Affiliations: Frederick National Laboratory for Cancer Research (US)
University of Florida (US)
ORCID: Largaespada, David A.
Jenkins, Nancy A.
Venue: Nature Genetics
Publisher: Springer Science and Business Media LLC
Published: 1996-02
Volume: 12
Issue: 2
Pages: 137-143
ISSN: 1061-4036 (ISSN-L)
1546-1718
DOI: 10.1038/ng0296-137
OpenAlex: W2087533846
Cited by: 284
References: 33
Citations by year: 2025: 2 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 6 · 2018: 4 · 2017: 3 · 2016: 8 · 2015: 4 · 2014: 4 · 2013: 6 · 2012: 14
FWCI: 15.71
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Genetics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords: neurofibromatosis type 1, NF1 deficiency, Ras signaling, GM-CSF, GM-CSF hypersensitivity, chronic myeloid leukemia, myeloproliferative neoplasms, hematopoietic stem cells, genetic screen, Ras GTPase-activating protein
MeSH terms: Acute Disease, Animals, Bone Marrow, Cell Differentiation, Cell Line, Transformed, Crosses, Genetic, Disease Models, Animal, Female, Guanosine Triphosphate, Hematopoietic Stem Cells, Humans, Leukemia, Myeloid, Liver, Male, Mice, Inbred C57BL, Signal Transduction, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Granulocyte-Macrophage Colony-Stimulating Factor, Genes, Neurofibromatosis 1, Hematopoietic Stem Cell Transplantation, Disease Progression, ras Proteins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nf1 deficiency causes Ras-Dediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks